Compare Charles River Laboratories Intl. Inc (CRL) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $232.76 (market cap $11.14B), while YieldMax MSTR Option Income Strategy ETF trades at $13.31. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CRL | MSTY | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $233.60 | $114.30 |
52-Week Low | $145.57 | $11.55 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
MSTY trades at $12.57, down 2.03% with bearish technical signals from moving averages. The ETF maintains aggressive weekly dividend distributions, though recent coverage highlights concerns about return of capital and NAV erosion. Technical indicators show RSI in neutral territory while moving averages signal continued downward pressure.
The outlook remains challenging with structural risks to the covered-call strategy capping upside potential while exposing investors to full downside. Recent analyst commentary emphasizes unsustainable yield dynamics and dependence on Bitcoin volatility. Investment requires careful consideration of distribution sustainability versus capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
